Merck Tbk PT

Merck Tbk PT maintains a strong liquidity position, with a current ratio of 4.26, indicating the company can cover its short-term liabilities more than four times over. The company's liquidity FPT (free cash flow to total liabilities) is robust, supported by a free cash flow of IDR 184.6 billion and total liabilities of IDR 296.5 billion. The company's price-to-book ratio of 1.96 and price-to-tangible-book ratio of 1.96 suggest that the market values the company at a premium to its book value, which is in line with the industry's preference for tangible asset valuation. In terms of profitability, Merck Tbk PT reports a return on equity (ROE) of 25% and a return on assets (ROA) of 19.17%, both of which are strong indicators of efficient capital use and asset management. These figures are well above the industry median for ROE and ROA, which typically hover around 15% and 10%, respectively. The company's operating margin, calculated as operating income of IDR 320.3 billion on revenue of IDR 1.2 trillion, is approximately 26.7%, which is also above the industry median of 20%. Merck Tbk PT's revenue is split between its Biopharma and Consumer Health segments. The Biopharma segment, which focuses on ethical products, is likely the larger contributor to revenue, though the exact split is not disclosed. The company's geographic exposure is primarily within Indonesia, with some offshore sales, but the extent of international revenue is not specified in the available data. The company's growth trajectory is positive, with a price-to-earnings ratio of 7.84 and an enterprise value to EBITDA ratio of 6.02, both of which are below the industry median, suggesting the company is undervalued relative to its earnings and cash flow. The company's outlook for the current fiscal year includes a projected increase in revenue and earnings, supported by its strong cash flow and low debt levels. Risk factors for Merck Tbk PT include a medium liquidity risk, as the company has a net cash position that is negative after subtracting total debt. The dilution risk is low, with no significant dilution sources identified in the available data. The company's debt-to-equity ratio of 0.01 indicates a conservative capital structure, with minimal reliance on debt financing. Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's recent financial performance and disclosures suggest a stable and growing business, with no immediate signs of financial distress or operational challenges.